State of the art and future perspectives of new radionuclides in Nuclear Medicine.

This continuing education analyzes recent advances in Nuclear Medicine focused on the development of new radiopharmaceuticals that improve both the diagnosis and treatment of complex diseases. The focus is on teragnosis, which combines diagnosis and treatment by means of pairs of radiopharmaceuticals directed to the same molecular target, which allows the personalization of treatments. This first part specifically reviews the teragnostic pairs copper-64/copper-67, lead-212/lead-203 and scandium-44/scandium-47, highlighting their physical characteristics, methods of production and potential clinical applications. Despite the challenges in their production, their versatility and effectiveness are driving their clinical application in oncology and other diseases. The text also addresses the development of new radiopharmaceuticals and their impact on precision medicine, pointing out future directions and opportunities for research in this field.